Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen

[1]  J. Bergh,et al.  Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Trevor Hastie,et al.  Averaged gene expressions for regression. , 2007, Biostatistics.

[3]  Caroline C. Friedel,et al.  Reliable gene signatures for microarray classification: assessment of stability and performance , 2006, Bioinform..

[4]  Zhiyuan Hu,et al.  Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. J. van de Vijver,et al.  Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.

[6]  Manuela Gariboldi,et al.  Limits of predictive models using microarray data for breast cancer clinical treatment outcome. , 2005, Journal of the National Cancer Institute.

[7]  Stefan Michiels,et al.  Prediction of cancer outcome with microarrays: a multiple random validation strategy , 2005, The Lancet.

[8]  Maurice P H M Jansen,et al.  Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Eytan Domany,et al.  Outcome signature genes in breast cancer: is there a unique set? , 2004, Breast Cancer Research.

[10]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[11]  D. Cameron,et al.  Tamoxifen treatment failure in cancer and the nonlinear dynamics of TGFbeta. , 2004, Journal of theoretical biology.

[12]  Wei Wang,et al.  A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. , 2004, Cancer cell.

[13]  R. Tibshirani,et al.  Semi-Supervised Methods to Predict Patient Survival from Gene Expression Data , 2004, PLoS biology.

[14]  Y. Rao,et al.  Slit Protein-mediated Inhibition of CXCR4-induced Chemotactic and Chemoinvasive Signaling Pathways in Breast Cancer Cells* , 2004, Journal of Biological Chemistry.

[15]  Philipp Bucher,et al.  CleanEx: a database of heterogeneous gene expression data based on a consistent gene nomenclature , 2004, Nucleic Acids Res..

[16]  W. Hung,et al.  RECK is a target of Epstein–Barr virus latent membrane protein 1 , 2003, Oncogene.

[17]  Philip M. Long,et al.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[19]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Josef Kittler,et al.  Combining classifiers , 1996, Proceedings of 13th International Conference on Pattern Recognition.

[21]  W. G. Cochran.  Problems arising in the analysis of a series of similar experiments , 1937 .